

## Results of 2016 Annual General Meeting

LivaNova PLC (the “**Company**” or “**LivaNova**”) announces that, on 16 June 2016, LivaNova filed with the U.S. Securities and Exchange Commission its Current Report on Form 8-K.

The Annual General Meeting of LivaNova PLC was held on Wednesday 15 June 2016 at the offices of Latham & Watkins (London) LLP, 99 Bishopsgate, London EC2M 3XF. A poll was held for each resolution. The table below shows the number of votes received for and against each resolution together with the votes validly cast, both as a total and as a proportion of the issued share capital.

For presentation purpose, the description of the resolutions in the table below has been abbreviated. Reference should be made to the full resolutions as set out in the notice of meeting sent to shareholders or to the full copy of the resolutions to be uploaded on the National Storage Mechanism.

	For (Number of Votes)	Percent For (%)	Against (Number of Votes)	Percent Against (%)	Total votes validly cast	Total votes validly cast as a percentage of shares in issue (%)	Abstentions (Number of votes)
1. To receive and adopt the audited UK statutory accounts.	37,090,847	99.31	12,756	0.03	37,103,603	75.61	243,914
2. To approve the directors' remuneration report (excluding policy).	34,111,340	91.33	3,191,816	8.54	37,303,156	76.02	44,301
3. To approve the directors' remuneration policy.	32,806,406	87.84	2,699,096	7.22	35,505,502	72.35	1,842,015
4. To re-appoint PricewaterhouseCoopers LLP as the UK statutory auditor.	37,298,092	99.86	17,352	0.04	37,315,444	76.04	32,073

Resolutions	For (Number of Votes)	Percent For (%)	Against (Number of Votes)	Percent Against (%)	Total votes validly cast	Total votes validly cast as a percentage of shares in issue (%)	Abstentions (Number of votes)
5. To ratify the appointment of Pricewaterhouse Coopers S.p.A. as the independent registered public accounting firm.	37,297,926	99.86	17,558	0.04	37,315,484	76.04	32,033
6. To authorise the directors and/or the Audit & Compliance Committee to determine the remuneration of PricewaterhouseCoopers LLP.	37,291,728	99.85	18,871	0.05	37,310,599	76.03	36,918
7. To approve the form of share repurchase contracts and the counterparties for repurchases on the NASDAQ Global Market.	34,617,720	92.69	2,631,432	7.04	37,249,152	75.91	98,365
8. To authorise on-market purchases of shares on the London Stock Exchange.	37,234,915	99.69	14,089	0.03	37,249,004	75.91	98,513
9. To authorise the Company to send notices, documents or information by electronic means.	37,289,862	99.84	14,369	0.03	37,304,231	76.02	43,286
<b>Special Resolutions</b>							
10. To authorise general meetings, to be held on not less than 14 clear days' notice.	31,784,141	85.10	3,882,080	10.39	35,666,221	72.68	1,681,296

The number of Ordinary Shares in issue on Monday 13 June 2016 at 6 pm (there being no shares held in Treasury) was 49,069,828. Shareholders are entitled to one vote per share. An abstention is not a vote in law and is not counted in the calculation of the proportion of votes validly cast.

A copy of the Resolutions (including Special Resolutions) passed at the Annual General Meeting is being submitted to the UK Listing Authority via the National Storage Mechanism and will shortly be available for inspection at: <http://www.morningstar.co.uk/uk/nsm>.

## **About LivaNova**

LivaNova PLC, headquartered in London, UK, is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics, Inc., a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals, and healthcare systems. The Company employs approximately 4,600 employees worldwide. With a presence in more than 100 countries, LivaNova operates as three business units: Cardiac Rhythm Management, Cardiac Surgery, and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.), respectively.

LivaNova is listed on NASDAQ and listed on the Official List of the UK's Financial Conduct Authority and traded on London Stock Exchange (LSE) under the ticker symbol "LIVN".

For more information, please visit [www.livanova.com](http://www.livanova.com), or contact:

## **Investor Relations and Media**

### **Karen King**

Vice President, Investor Relations & Corporate Communications

Phone: +1 (281) 228-7262

Fax: +1 (281) 218-9332

e-mail: [corporate.communications@livanova.com](mailto:corporate.communications@livanova.com)